InsidersTradesSigma
Follow the Travere Therapeutics, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Travere Therapeutics, Inc. has recorded 265 public disclosures. Market capitalisation: €6.2bn. The latest transaction was reported on 3 September 2026 (Cession). Among the most active insiders: REED ELIZABETH E. The full history is openly available.
265
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€14m
101 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Travere Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$74.14.
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,949 of 29,063 companies
31.4
score / 100
Value34
Quality29
FCF yld-0.3%
Earn yld-0.4%
EV/EBITDA·
ROE-236%
Gross mgn98%
Net mgn-5.2%
Debt/EBITDA14.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 3 September 2026
Declarations265 total
642 shares@ US$66.37Common StockSEC:0001943192-26-000005:0
2,600 shares@ US$63.49990.0028% mcap9.7% of flowCommon StockSEC:0001123343-26-000010:2
5,000 shares@ US$17.440.0015% mcap5.1% of flowCommon StockSEC:0001123343-26-000010:0
1,900 shares@ US$62.52890.0020% mcap7.0% of flowCommon StockSEC:0001123343-26-000010:1
500 shares@ US$64.1620.0005% mcap1.9% of flowCommon StockSEC:0001123343-26-000010:3
5,000 shares@ US$17.440.0015% mcap5.1% of flowCommon StockSEC:0001123343-26-000010:4
4,100 shares@ US$63.26590.0044% mcap15.3% of flowCommon StockSEC:0001123343-26-000010:5
900 shares@ US$63.85570.0010% mcap3.4% of flowCommon StockSEC:0001123343-26-000010:6
5,000 shares@ US$63.530.0053% mcap100.0% of flowCommonSEC144:0001950047-26-008327
5,000 shares@ US$62.140.0052% mcap100.0% of flowCommonSEC144:0001950047-26-008242
4,500 sharesCommon StockSEC:0001680739-26-000014:0
4,500 sharesCommon StockSEC:0001680739-26-000014:1
10,000 sharesCommon StockSEC:0001376043-26-000010:0
10,000 sharesCommon StockSEC:0001376043-26-000010:1
4,500 shares@ US$50.000.0042% mcap100.0% of flowCommonSEC144:0001950047-26-005979
10,000 shares@ US$50.0430.0094% mcap79.3% of flowCommonSEC144:0001376043-26-000007
4,000 shares0Common StockSEC:0001680739-26-000012:0
4,000 shares0Common StockSEC:0001517790-26-000002:0
4,000 shares0Common StockSEC:0001376043-26-000006:0
9,100 shares@ US$39.090.0064% mcap53.6% of flowCommon StockSEC:0001698262-26-000003:0
8,000 shares@ US$17.940.0026% mcap4.7% of flowCommon StockSEC:0001680739-26-000005:0
9,000 shares@ US$15.430.0025% mcap4.5% of flowCommon StockSEC:0001680739-26-000005:1
4,500 shares@ US$18.270.0015% mcap2.7% of flowCommon StockSEC:0001680739-26-000005:2
4,500 shares@ US$21.380.0017% mcap3.2% of flowCommon StockSEC:0001680739-26-000005:3
6,750 shares@ US$17.110.0021% mcap3.8% of flowCommon StockSEC:0001680739-26-000005:4
25 of 265 declarations
关于 Travere Therapeutics, Inc.
Travere Therapeutics, Inc. 是一家总部位于美国圣迭戈的生物制药公司，在纳斯达克上市，股票代码为 TVTX。Travere 是一家专注于罕见疾病的专业公司，重点关注肾脏病学和相关的孤儿疗法机会。该公司成立于 2008 年，现已发展成为一个商业化平台，结合了药物开发、监管执行和有针对性的专业销售模式。Travere 将自己描述为一家致力于为罕见病患者识别、开发和提供改变生命的疗法的公司，这既构成了其研发战略，也构成了其市场定位。([sec.gov](https://www.sec.gov/Archives/edgar/data/1438533/000143853324000014/travereannualreportars.pdf?utm_source=openai)) Travere 的商业故事日益以 FILSPARI® (sparsentan) 为中心，这是其用于罕见肾脏病的主要产品。公司近期披露的信息显示，到 2026 年，美国净产品销售额将实现显著增长，这反映了更强的市场接受度和持续的商业势头。一个关键里程碑发生在 2026 年 4 月，当时 FDA 完全批准了 FILSPARI，用于减少 8 岁及以上患有局灶性节段性肾小球硬化症 (FSGS) 且无肾病综合征的成人和儿童患者的蛋白尿。该批准扩大了该药物的适用临床范围，并巩固了其作为产品组合中主要价值驱动因素的作用。Travere 还通过 Travere TotalCare® 支持治疗启动和依从性，这是一个为患者、护理人员和医疗保健提供者设计的患者支持计划。([ir.travere.com](https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-Full-FDA-Approval-of-FILSPARI-sparsentan-the-First-and-Only-Approved-Medicine-for-FSGS/default.aspx?utm_source=openai)) 从竞争角度来看，Travere 是一家专注的专业公司，而非一家规模化的多元化制药公司。其优势在于在罕见病领域运营，在该领域，当数据具有说服力时，临床差异化、监管壁垒和报销复杂性可以减少直接竞争并支持溢价定价。该公司的战略依赖于扩大 FILSPARI 的适应症、将商业势头转化为可持续收入，并推进其研发管线和合作伙伴关系。Travere 还报告了国际合作，包括与日本的 Chugai Pharmaceutical 和欧洲部分地区的 CSL 的合作，这表明了选择性的全球扩张战略。尽管如此，该公司仍然面临典型的生物技术风险：上市执行、支付方准入、生产规模扩大、监管结果和竞争动态。([ir.travere.com](https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results/default.aspx?utm_source=openai)) 对于投资者而言，Travere 代表了一个专注于罕见疾病并拥有重要商业主导资产的医疗保健/制药增长故事。该公司不是一家基础广泛的制药巨头；相反，它是一家利基专业公司，其股权案例取决于 FILSPARI 的采用、适应症的扩大、国际合作伙伴关系和研发管线的执行。2026 年的最新更新和季度销售趋势表明基本面正在改善，而该股票仍然具有专业生物制药公司典型的较高波动性和事件风险。([ir.travere.com](https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Announces-Full-FDA-Approval-of-FILSPARI-sparsentan-the-First-and-Only-Approved-Medicine-for-FSGS/default.aspx?utm_source=openai))
